Weight Loss Drug Adherence Drops, Companies Push for Oral Alternatives

Studies reveal low long-term adherence to GLP-1 injections, prompting a surge in the development of more convenient weight loss pills.

Only 15% of patients continue GLP-1 injections for weight loss after two years, according to recent studies.
Drugmakers like Pfizer and Novo Nordisk are developing oral weight loss drugs to address adherence issues.
Oral alternatives may alleviate supply shortages and potentially lower costs compared to injectable treatments.
Pfizer's once-daily obesity pill, danuglipron, shows promise but faces competition from rivals with more advanced trials.
The weight loss drug market is expected to grow to $130 billion by the end of the decade.